Ipamorelin + Thymosin Alpha-1 Stack: Complete Protocol

Why These Two Peptides Are Combined

Practitioners who use this stack are targeting two physiological systems at once: the growth-hormone axis and the immune system. Ipamorelin drives GH pulsatility through the ghrelin receptor (GHSR-1a). Thymosin Alpha-1 acts on Toll-like receptors 2 and 9, dendritic cells, and T-regulatory cell populations to modulate immune surveillance.

Because the receptor systems do not overlap, the two peptides do not compete for binding sites, and no direct pharmacokinetic interactions have been reported in animal or human literature. That mechanistic separation is the core rationale for stacking them.

What Ipamorelin Does

Ipamorelin is one of the most selective GHRPs identified to date. Unlike GHRP-2 or GHRP-6, it produces negligible cortisol or prolactin release at therapeutic doses, a property confirmed in a 1998 pharmacology study showing the specificity of its GH release profile compared with older secretagogues (Raun et al., Eur J Endocrinol, 1998). GH pulses downstream into IGF-1 production in the liver, which drives most of the anabolic, lipolytic, and tissue-repair effects attributed to the GH axis.

What Thymosin Alpha-1 Does

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 by Goldstein and colleagues in the 1970s. It is not a growth-hormone compound at all. Its documented actions include increasing natural killer cell activity, promoting T-helper-1 cytokine responses, and reducing inflammatory cytokine burden in chronic viral and oncology contexts (Goldstein et al., J Immunol, 1977). The synthetic version, thymalfasin, received regulatory approval in 37 countries for hepatitis B and hepatitis C, and it has been studied extensively in sepsis and COVID-19 populations.

Why They Are Paired

The logic is additive, not synergistic in any pharmacological sense. A person seeking accelerated tissue recovery from training, surgery, or illness might want GH-axis support for repair kinetics and immune support to reduce susceptibility to infection during a period of elevated physiological stress. Neither peptide augments or inhibits the other based on current mechanistic data.

Evidence Quality: What the Research Actually Shows

Most peptide stacks lack randomized controlled trial data. This stack is no exception. Understanding the evidence tiers for each agent individually matters before combining them.

Ipamorelin Evidence

Ipamorelin has been studied in human clinical trials for postoperative ileus (ClinicalTrials.gov NCT00902642) and in phase II trials for gastroparesis, where oral formulations were investigated. The original dose-ranging pharmacology work was conducted in rats, where ipamorelin at 125 mcg/kg produced statistically significant GH spikes without measurable cortisol elevation (Raun et al., 1998). Human GH secretagogue studies more broadly confirm that GHSR-1a agonism can raise serum IGF-1 by 20 to 30% in growth-hormone-deficient adults, as shown with the related compound MK-677 over 12 months in a trial published in the Journal of Clinical Endocrinology and Metabolism (Murphy et al., JCEM, 1998).

Ipamorelin-specific human IGF-1 data are sparse outside proprietary datasets. Practitioners extrapolate from the GHRP class literature and from MK-677 trials because the receptor target is the same.

Thymosin Alpha-1 Evidence

Thymosin Alpha-1 carries a heavier evidence base. A meta-analysis of 16 randomized trials in hepatitis B patients (N=1,000+) found thymalfasin produced higher rates of HBeAg seroconversion than placebo or interferon monotherapy in several arms (Iino et al., Hepatol Res, 2005). In sepsis, a Chinese multicenter RCT (N=361) published in JAMA Internal Medicine found thymalfasin reduced 28-day mortality relative to standard care in patients with sepsis-induced immunosuppression (Wu et al., JAMA Intern Med, 2013).

During COVID-19, observational data from Italian centers suggested thymalfasin at 1.6 mg twice weekly reduced severity and mortality signals, though confounding limits interpretation (Zheng et al., Clin Immunol, 2020).

None of these trials included Ipamorelin as a co-treatment. The immune benefits observed for Thymosin Alpha-1 are its own; they do not depend on GH-axis co-stimulation.

The Evidence Gap for the Combination

No published human trial has examined Ipamorelin and Thymosin Alpha-1 together. Practitioners who use this stack rely on mechanistic extrapolation and case-series reporting. Patients considering this stack should understand that the combination's safety and efficacy profile comes from individual-peptide data, not from a trial that studied them jointly.

Complete Dosing Protocol

This section presents the dosing framework most commonly reported among prescribing clinicians and compounding-pharmacy documentation. Doses should be confirmed with a licensed prescriber and individualized based on labs and clinical context.

Ipamorelin Dosing

Starting dose: 200 mcg subcutaneous injection per administration. Titration: Increase to 300 mcg per administration if no adverse effects appear after 2 weeks. Some protocols go to 300 to 500 mcg, though doses above 300 mcg show diminishing returns on GH pulse amplitude in most GHRP literature. Frequency: 2 to 3 times daily, spaced at least 3 hours apart to allow GH trough recovery between pulses. Timing: The most pharmacologically rational administration windows are upon waking (before food), pre-workout or pre-activity, and at bedtime (fasted, at least 2 hours after the last meal). GH release is blunted by hyperglycemia; carbohydrate proximity to injection reduces efficacy. Injection site: Subcutaneous, abdomen or lateral thigh, rotating sites.

Thymosin Alpha-1 Dosing

Standard clinical dose: 1.5 mg subcutaneous twice per week, based on the dose used in the hepatitis B and sepsis trial literature (Wu et al., JAMA Intern Med, 2013). Frequency for immune optimization (non-disease context): Some practitioners reduce to 1.0 to 1.5 mg once weekly in patients without acute immune compromise, citing cost and the long biological half-life of immune priming effects. Injection site: Subcutaneous, upper arm or abdomen. Reconstitution: Bacteriostatic water (1 mL per vial is typical). Stable refrigerated for 30 days after reconstitution.

Timing of Each Peptide Relative to the Other

There is no pharmacokinetic reason to separate the injections by specific hours. Both are subcutaneous and absorb via the lymphatic and capillary routes into systemic circulation independently. Rotating anatomical sites for each injection on the same day is good practice. Many patients inject Thymosin Alpha-1 on Monday and Thursday mornings, then Ipamorelin three times daily on all seven days.

Cycle Length and Off Periods

Recommended Cycle Duration

Most practitioners run this stack for 8 to 16 weeks. The 8-week minimum reflects the time needed for IGF-1 stabilization and measurable immune-cell subset changes. The 16-week ceiling is a practical limit used to preserve receptor sensitivity.

GH secretagogues can reduce endogenous GHRH pulsatility with prolonged continuous use if somatostatin feedback upregulates. A structured off period resets sensitivity. Evidence for exactly how long off periods need to be is limited; a 4-week break after every 12-week cycle is the most commonly cited clinical framework.

Thymosin Alpha-1 immune effects appear durable for weeks after cessation based on hepatitis B trial follow-up data, so off-period immune support should not be a concern for most users.

Monitoring During the Cycle

Labs to obtain before starting and at the 6 to 8 week mark:

• IGF-1 (serum): Baseline and on-cycle. Target the upper quartile of age-adjusted normal range, not supraphysiologic. The GH Research Society defines adult IGF-1 excess risk above +2 SD for age (GH Research Society Consensus, JCEM, 2000).
• Fasting glucose and HbA1c: GH secretagogues may impair insulin sensitivity at high doses or in predisposed individuals.
• CBC with differential: Thymosin Alpha-1 promotes T-cell expansion; baseline white-cell counts help interpret any on-cycle changes.
• CMP: Liver and kidney function, especially if using other compounds concurrently.
• Cortisol (morning): Ipamorelin should not raise cortisol meaningfully; an elevation prompts reassessment of dose or compound authenticity.

Who Is This Stack For

Potential Clinical Contexts

Practitioners most commonly consider this stack for patients in one of three scenarios:

1. Post-surgical or post-injury recovery, where GH-axis support for collagen synthesis and immune resilience are both desired simultaneously.
2. Aging adults with documented low-normal IGF-1 and a history of recurrent infections or suboptimal immune function on standard workup.
3. Oncology-adjacent support, in which thymalfasin's established literature in cancer-related immunosuppression is relevant and a prescribing oncologist approves.

Who Should Not Use This Stack

Patients with active malignancy should not use GH secretagogues without explicit oncologist approval. IGF-1 elevation is a plausible mitogenic signal for certain tumors, and the American Association of Clinical Endocrinology notes caution with GH-axis activation in patients with a personal history of malignancy (AACE Growth Hormone Guidelines).

Pregnancy and breastfeeding are absolute contraindications. Both peptides lack adequate safety data in these populations.

Patients with uncontrolled diabetes or glucose intolerance should have their glucose management optimized before adding a GH secretagogue, given the insulin-antagonist effects of sustained IGF-1 and GH elevation.

Injection Technique and Reconstitution

Reconstituting Lyophilized Peptides

Both peptides arrive as white lyophilized powder in sealed vials. Standard reconstitution uses bacteriostatic water (BAC water, 0.9% benzyl alcohol preserved).

• Draw BAC water volume (typically 1 to 2 mL per vial) into an insulin syringe.
• Insert needle at an angle into the rubber stopper.
• Allow water to run down the glass wall, not directly onto the powder. This prevents protein denaturation.
• Swirl gently. Do not shake.
• Allow to sit at room temperature for 2 to 3 minutes until fully dissolved.
• Refrigerate at 2 to 8°C. Use within 28 to 30 days.

Subcutaneous Injection Steps

• Clean injection site with an alcohol swab and allow to dry completely.
• Pinch a skin fold (1 to 2 cm) with non-dominant hand.
• Insert a 29- or 31-gauge insulin syringe at 45 degrees for lean individuals, 90 degrees for those with more subcutaneous tissue.
• Inject slowly. Release the skin fold. Apply light pressure.
• Rotate sites systematically to avoid lipohypertrophy.

Potential Side Effects and How to Manage Them

Ipamorelin Side Effects

The most commonly reported adverse effect is transient facial flushing or warmth in the 10 to 20 minutes following injection, attributed to GH-pulse vasodilation. Water retention, particularly in the first 2 to 4 weeks, reflects IGF-1-mediated sodium retention and typically resolves with continued use or dose reduction.

Hunger increase is reported with older GHRPs like GHRP-6 but is substantially attenuated with Ipamorelin due to its receptor selectivity (Raun et al., 1998). Carpal tunnel symptoms at high doses mirror those seen with exogenous GH therapy and respond to dose reduction.

Headache within 30 minutes of injection suggests a dose that is too high for the individual's GH-axis sensitivity. Reduce from 300 mcg to 200 mcg and reassess.

Thymosin Alpha-1 Side Effects

The hepatitis B trial literature and the sepsis RCT both describe an excellent tolerability profile. Injection-site reactions (mild redness, transient induration) are the most frequent complaint, occurring in roughly 5 to 10% of participants across clinical trials. Systemic adverse events were not statistically elevated above placebo in the JAMA Internal Medicine sepsis trial (Wu et al., 2013).

Fatigue in the first week is occasionally reported, possibly reflecting an acute immune-reorganization phase. It resolves in most cases by day 10.

Drug Interactions

Thymosin Alpha-1 has been studied alongside interferon alfa and nucleoside analogues in hepatitis trials without significant pharmacodynamic interactions. Ipamorelin has no well-documented drug interactions in the published literature. Both peptides should be used with caution alongside systemic corticosteroids, which blunt immune responses and suppress GH-axis feedback, reducing the utility of both compounds.

Comparing This Stack to Alternatives

Practitioners sometimes debate whether adding CJC-1295 (a GHRH analogue) with Ipamorelin instead of Thymosin Alpha-1 addresses the same goals. It does not. CJC-1295 amplifies GH pulse amplitude further but adds nothing to immune regulation. The CJC-1295 + Ipamorelin combination produces a larger IGF-1 rise, which some patients want; the Ipamorelin + Thymosin Alpha-1 pairing trades some of that IGF-1 ceiling for immune-modulating coverage.

A 2006 pharmacology study of CJC-1295 confirmed sustained IGF-1 increases of 20 to 30% over 28 days in healthy adults (Ionescu et al., JCEM, 2006), showing the GH-axis effect is strong as a standalone. Adding Thymosin Alpha-1 to that platform (a three-peptide stack) is done in some protocols but demands careful monitoring of both IGF-1 and immune markers.

Regulatory and Compounding Considerations

Neither Ipamorelin nor Thymosin Alpha-1 is FDA-approved for bodybuilding, anti-aging, or general wellness indications. Thymalfasin (Zadaxin) holds regulatory approval in more than 37 countries for viral hepatitis, but not in the United States as of January 2025. The FDA's 2023 and 2024 guidance documents have specifically addressed GHRP compounds, placing several on the Category 2 list of bulk drug substances that may not be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDA 503A Bulks List).

Patients should confirm the legal compounding status of both peptides in their jurisdiction with their prescribing physician before initiating treatment. Purchasing either compound from non-pharmacy, non-prescriber sources carries risks of purity, sterility, and underdosing that make clinical outcomes unpredictable.

Practical Sample Week

| Day | Ipamorelin (200 to 300 mcg SC) | Thymosin Alpha-1 (1.5 mg SC) | |---|---|---| | Monday | AM / Pre-workout / PM | Yes (morning) | | Tuesday | AM / Pre-workout / PM | No | | Wednesday | AM / Pre-workout / PM | No | | Thursday | AM / Pre-workout / PM | Yes (morning) | | Friday | AM / Pre-workout / PM | No | | Saturday | AM / Pre-workout / PM | No | | Sunday | AM / Pre-workout / PM | No |

This schedule delivers 21 Ipamorelin injections per week (three times daily) and 2 Thymosin Alpha-1 injections per week, matching the hepatitis and sepsis trial dosing frequency.